SUTRO BIOPHARMA, INC. - 10-Q Filing
Sutro Biopharma reports Q3 2025 financial results highlighting ongoing R&D investment and collaboration activities with Astellas, Ipsen, and Vaxcyte.
Tickers: $STRO
Sutro Biopharma reports Q3 2025 financial results highlighting ongoing R&D investment and collaboration activities with Astellas, Ipsen, and Vaxcyte.
Tickers: $STRO